Welcome to our dedicated page for Adia Nutrition news (Ticker: ADIA), a resource for investors and traders seeking the latest updates and insights on Adia Nutrition stock.
Adia Nutrition Inc. (OTCQB: ADIA) generates frequent news and updates centered on its work in regenerative medicine, stem cell therapies, and wellness-focused healthcare. Company announcements highlight developments across its Adia Med clinical platform, Adia Labs regenerative product division, and related health and wellness investments.
Recent news has focused on Adia Med of Winter Park’s Autism Spectrum Disorder (ASD) clinical study, a randomized interventional trial listed on ClinicalTrials.gov (NCT07304440). Releases describe IRB approval from BeyondBound, the study’s design comparing glutathione alone to glutathione combined with AdiaVita, and the launch of patient recruitment for approximately 100 children ages 3–12. These updates provide insight into Adia’s clinical research pipeline and its approach to combining antioxidants with umbilical cord blood-derived stem cells and exosomes.
News items also cover corporate and capital markets milestones, such as Adia’s uplisting to the OTCQB Venture Market, completion of SEC Rule 15c2‑11 requirements, and the filing of a Form 10 registration statement as a step toward full reporting status. Operational highlights include revenue growth commentary, expansion of the company’s sales infrastructure, partnerships that extend clinic oversight and marketing capabilities, and initiatives to broaden access to Adia Labs products and Adia Med services.
Additional coverage features partnerships and leadership appointments, including collaborations with media and marketing organizations and the addition of senior executives to support revenue generation and clinic network expansion. Visitors to this ADIA news page can review these releases to follow Adia Nutrition’s clinical studies, regenerative therapy offerings, clinic partnerships, and regulatory progress over time.
Adia Nutrition Inc. (OTC Pink: ADIA) has achieved a significant milestone by successfully removing its shell risk designation from OTC Markets, marking a important step toward uplisting from OTC Pink Sheets to the OTCQB Venture Market. This development enhances the company's market position and demonstrates its commitment to operational transparency.
The removal of the shell risk designation, a critical requirement for OTCQB status, was accomplished through close collaboration with OTC Markets. The company has been actively working to meet all uplisting criteria, including completing a comprehensive third-party audit.
CEO Larry Powalisz expressed enthusiasm about this achievement, indicating it will enable greater information sharing with investors. The OTCQB Venture Market is expected to provide enhanced transparency, liquidity, and investor trust, allowing Adia Nutrition to better showcase its stem cell therapies and nutritional products portfolio.
ADIA Nutrition Inc. (OTC Pink: ADIA) has announced a strategic nationwide expansion plan for Adia Med satellite locations through partnerships with premier Medical Spas. The initiative focuses on making their regenerative medicine treatments more accessible across the United States.
The expansion strategy involves collaborating with established Med Spas to offer Umbilical Cord Stem Cell therapies, stem cell injectables, and other regenerative solutions. The company will implement a phased approach, starting with pilot programs in major cities and affluent suburbs with health-conscious demographics.
The business model includes multiple revenue streams through service fees, royalties, and potential equity interests. ADIA will provide comprehensive training and quality control measures to maintain consistent treatment standards across all locations. CEO Larry Powalisz emphasized that successful Med Spas will benefit from a generous commission structure and increased patient base.
ADIA Nutrition (OTC Pink: ADIA) has launched Adia Labs , a new division focused on regenerative medicine. The company introduces two key products: AdiaVita, a private-label umbilical cord stem cell product guaranteeing 100 million viable cells and 3 trillion exosomes per unit, and AdiaLink, an upcoming product offering 3.5 trillion exosomes per unit.
The launch was enabled through a partnership with an FDA-approved laboratory, allowing ADIA to offer these products under its own brand. The products are specifically designed for clinical research, studies, and trials, targeting a potential client base of over one million doctors and clinics nationwide.
These products aim to address various conditions, including autoimmune diseases, degenerative disorders, and injury recovery, focusing on non-invasive biological treatments. Doctors and clinics can purchase these products through adialabs.com.
Adia (ADIA) has announced a strategic partnership with an FDA-approved laboratory specializing in regenerative medicine. The collaboration focuses on providing high-quality umbilical cord stem cell and exosome products. The lab's products feature 100 million umbilical cord stem cells and 3 trillion exosomes per dose.
The partnership highlights several key attributes: FDA approval ensuring safety and quality protocols for biologics, third-party verification for product quality, minimal manipulation techniques to preserve therapeutic properties, and research excellence in identifying optimal umbilical cord stem cell sources. The products are intended for various therapeutic applications, including orthopedics, neurology, and dermatology.
The company aims to distribute these advanced products for clinical trials, therapeutic use, and preventive medicine applications, particularly in anti-aging and wellness treatments.
Adia Med, the medical division of Adia Nutrition (OTC Pink: ADIA), is pursuing registration with Florida's Agency for Health Care Administration (AHCA) to accept private insurance for its stem cell therapies. This initiative aims to expand access to their Autologous Hematopoietic Stem Cell Transplantation (aHSCT) and injectable stem cell treatments.
Currently operating on an out-of-pocket payment model, the company aims to reduce financial barriers through insurance coverage. The company has engaged specialized consultants for AHCA registration and financial documentation. Multiple potential clients have already received preapproval from private insurers for both HSCT and injectable stem cell therapies, indicating growing acceptance of these treatments in the insurance industry.
ADIA Nutrition Inc. (OTC Pink: ADIA) has discovered issues with approximately 25 million shares issued or committed without proper documentation over a decade ago. This includes 15 million currently outstanding shares and 10 million shares promised in a payment agreement before the current board's tenure. The company plans to retire these shares, which would reduce outstanding shares by about 15%.
Current share structure shows: 95,899,861 outstanding shares, 74,051,080 restricted shares, 21,848,781 unrestricted shares, 19,575,347 shares held at DTC, and a float of 13,848,781. The company is investigating additional restricted shares that might have been improperly issued. Management is working with legal advisors to properly retire the shares while maintaining operational focus on health and wellness initiatives, including umbilical cord stem cell treatments and HSCT for Multiple Sclerosis.
Adia Nutrition (OTC Pink: ADIA) has appointed a PCAOB accounting firm for a comprehensive third-party audit as part of its strategy to uplist from OTC Pink Sheets to the OTCQB Venture Market. This move aims to enhance visibility and attract more investors while demonstrating the company's commitment to transparency.
The uplisting to OTCQB is expected to provide several benefits, including increased transparency through higher reporting standards, greater market liquidity, enhanced investor confidence, and broader accessibility to investors. The company has outlined a roadmap to eventually list on the Nasdaq Small Cap, which involves completing the OTCQB uplisting, establishing SEC reporting, scaling operations to meet Nasdaq's standards, and ensuring adequate shareholder equity and public float.
Adia Nutrition (OTC Pink: ADIA) has entered the $15.1 billion global stem cell market through its medical division, Adia Med, with the opening of its first clinic in Winter Park, Florida. The facility offers stem cell treatments using FDA-compliant 361 human cell, tissue, and cellular and tissue-based products (HCT/Ps).
The company aims to provide treatments comparable to international locations like Panama, Mexico, Brazil, and Switzerland, but with the advantage of U.S.-based care. The clinic utilizes umbilical cord stem cells and focuses on treating conditions including inflammation, autoimmune conditions, and orthopedic issues.
Key advantages include quality stem cells from ethical sources, domestic convenience eliminating international travel, and operations under U.S. FDA health regulations emphasizing safety and transparency.
Adia Nutrition has unveiled an exclusive artwork by performance artist Rock Demarco at its clinic in Winter Park, Florida. The piece, featuring butterflies and stem cells, symbolizes transformation and healing through regenerative therapies. The artwork installation coincides with the announcement that the clinic has doubled its scheduled treatments for early January due to high demand.
Former WWE superstar Jeff Sciullo attended the unveiling ceremony, showing support for regenerative medicine and the MS community. The artwork will serve as an inspirational symbol for patients seeking treatments like Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for multiple sclerosis and other regenerative therapies for muscle injuries, joints, ligaments, and tendons.
Adia Nutrition has launched its first clinic in Winter Park, Florida, marking a significant expansion in regenerative medicine services. The new facility specializes in Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis patients and offers various regenerative therapies including stem cell treatments and platelet-rich plasma (PRP) procedures. The state-of-the-art clinic, strategically located in Winter Park, is now open and accepting patients, providing a dedicated environment for advanced medical treatments.
FAQ
What is the current stock price of Adia Nutrition (ADIA)?
What is the market cap of Adia Nutrition (ADIA)?
